Cancer and cardiovascular diseases have been classified as non-communicable diseases for decades. Both diseases have characteristics of immune reactions, which are principally identical, but differing in important aspects. The aim of this communication is to highlight new approaches to immune processes involved in both types of diseases.

Department of Pathology University of Louisville Louisville KY USA

Laboratory of Immunotherapy Institute of Microbiology Academy of Sciences Prague Czech Republic

See more in PubMed

Ehrlich P. Address in Pathology, ON CHEMIOTHERAPY: Delivered before the Seventeenth International Congress of Medicine. Br Med J 1913;2:353-9. 10.1136/bmj.2.2746.353 PubMed DOI PMC

Ehrlich P. The partial function of cells. (Nobel Prize address given on 11 December 1908 at Stockholm). Int Arch Allergy Appl Immunol 1954;5:67-86. 10.1159/000228089 PubMed DOI

Ehrlich P. Über den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneeskd 1909;5:273-90.

Burnet M. Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications. Br Med J 1957;1:841-7. 10.1136/bmj.1.5023.841 PubMed DOI PMC

Thomas L. Discussion of Cellular and humoral aspects of the hypersensitive states. In: Lawrence HS. editor. Cellular and Humoral Aspects of the Hypersensitive States: A Symposium held at the New York Academy of Medicine. New York: Hoeber, 1959:529-32.

Old LJ, Boyse EA. Immunology of Experimental Tumors. Annu Rev Med 1964;15:167-86. 10.1146/annurev.me.15.020164.001123 PubMed DOI

Stutman O. Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science 1974;183:534-6. 10.1126/science.183.4124.534 PubMed DOI

Stutman O. Immunodepression and malignancy. Adv Cancer Res 1975;22:261-422. 10.1016/S0065-230X(08)60179-7 PubMed DOI

Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045. 10.1146/annurev.iy.12.040194.005015 PubMed DOI

Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol 2003;21:807-39. 10.1146/annurev.immunol.21.120601.141135 PubMed DOI

Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45. 10.1016/S0140-6736(00)04046-0 PubMed DOI

Karin M, Cao Y, Greten FR, et al. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-10. 10.1038/nrc780 PubMed DOI

Dighe AS, Richards E, Old LJ, et al. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1994;1:447-56. 10.1016/1074-7613(94)90087-6 PubMed DOI

Vesely MD, Kershaw MH, Schreiber RD, et al. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011;29:235-71. 10.1146/annurev-immunol-031210-101324 PubMed DOI

Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21:137-48. 10.1016/j.immuni.2004.07.017 PubMed DOI

Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8. 10.1038/ni1102-991 PubMed DOI

Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology 2007;121:1-14. 10.1111/j.1365-2567.2007.02587.x PubMed DOI PMC

Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;473:298-307. 10.1038/nature10144 PubMed DOI PMC

Garrido F, Romero I, Aptsiauri N, et al. Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype. Int J Cancer 2016;138:271-80. 10.1002/ijc.29375 PubMed DOI

Borrego F, Ulbrecht M, Weiss EH, et al. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med 1998;187:813-8. 10.1084/jem.187.5.813 PubMed DOI PMC

Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci 2012;125:5591-6. 10.1242/jcs.116392 PubMed DOI

Alwan A, Armstrong T, Bettcher D, et al. Global status report on noncommunicable diseases, World Health Organization, 2011:1-162.

Yin C, Mohanta SK, Srikakulapu P, et al. Artery Tertiary Lymphoid Organs: Powerhouses of Atherosclerosis Immunity, Front Immunol 2016;7:387. 10.3389/fimmu.2016.00387 PubMed DOI PMC

Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 2011;145:341-55. 10.1016/j.cell.2011.04.005 PubMed DOI PMC

Robbins CS, Hilgendorf I, Weber GF, et al. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med 2013;19:1166-72. 10.1038/nm.3258 PubMed DOI PMC

Bekkering S, Joosten LA, van der Meer JW, et al. Trained innate immunity and atherosclerosis. Curr Opin Lipidol 2013;24:487-92. 10.1097/MOL.0000000000000023 PubMed DOI

Bekkering S, Quintin J, Joosten LA, et al. Oxidized low-density lipoprotein induces long-term proinflammatory cytokine production and foam cell formation via epigenetic reprogramming of monocytes. Arterioscler Thromb Vasc Biol 2014;34:1731-8. 10.1161/ATVBAHA.114.303887 PubMed DOI

Stevens WB, Netea MG, Kater AP, et al. 'Trained immunity': consequences for lymphoid malignancies. Haematologica 2016;101:1460-8. 10.3324/haematol.2016.149252 PubMed DOI PMC

Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010;464:1357-61. 10.1038/nature08938 PubMed DOI PMC

Akhavanpoor M, Gleissner CA, Akhavanpoor H, et al. Adventitial tertiary lymphoid organ classification in human atherosclerosis. Cardiovasc Pathol 2018;32:8-14. 10.1016/j.carpath.2017.08.002 PubMed DOI

Sima P, Vannucci L, Vetvicka V. Atherosclerosis as autoimmune disease. Ann Transl Med 2018;6:116. 10.21037/atm.2018.02.02 PubMed DOI PMC